Sobi's Tryngolza Receives EMA Validation for sHTG Treatment Indication Extension Sobi's Tryngolza has gained EMA validation for treating severe hypertriglyceridemia, marking a significant milestone in addressing patient needs.

Sobi's Tryngolza Receives EMA Validation for sHTG Treatment Indication Extension #Sweden #Stockholm #Sobi #Olezarsen #Tryngolza

Olezarsen lowers triglycerides and pancreatitis risk in severe hypertriglyceridemia Treatment with olezarsen may significantly reduce triglyceride levels and result in fewer acute pancreatitis events among adults with severe hypertriglyceridemia.

#MedNews - Treatment with #olezarsen may significantly reduce triglyceride levels and result in fewer acute #pancreatitis events among adults with severe #hypertriglyceridemia.

👉 buff.ly/UGgiUQY

#CardioSky

From the Chairman’s Corner In our new feature, TIMI Chairman Dr. Marc Sabatine discusses exciting trial results with TIMI Investigators Dr. Sabatine discusses the CORE (TIMI 72a) and CORE2 CS6-TIMI 72b AHA 25 LBCT results an…

Dive into the latest in cardiovascular research with 'From the Chairman's Corner', where Dr. Marc Sabatine discusses groundbreaking insights from the CORE and CORE2 TIMI trials and how #olezarsen is reshaping treatment for severe hypertriglyceridemia. timi.org/from-the-cha...

Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk | NEJM Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III messenger R...

En pacientes con hipertrigliceridemia grave el tratamiento con olezarsen conduce a una reducción en el nivel de triglicéridos a los 6m y de la incidencia de pancreatitis aguda #olezarsen #triglycerides www.nejm.org/doi/pdf/10.1...

Sobi’s Olezarsen Shows Promising Results for Treating Severe Hypertriglyceridemia A pivotal study of olezarsen presented at the AHA reveals significant benefits in treating severe hypertriglyceridemia, notably reducing acute pancreatitis events.

Sobi’s Olezarsen Shows Promising Results for Treating Severe Hypertriglyceridemia #Sweden #Stockholm #Sobi #Olezarsen #sHTG

From #ESCCongress 2025 - Dr. Brian Bergmark outlines the ESSENCE-TIMI 73b trial investigating #olezarsen in patients with moderate #hypertriglyceridemia and high cardiovascular risk.

Watch the full interview here 👉 buff.ly/cm1SuCn

#CardioSky #CVD

Tryngolza®: A Breakthrough Treatment Approved in the EU for FCS Patients Sobi and Ionis Pharmaceuticals celebrate the EU approval of Tryngolza® (olezarsen) for treating familial chylomicronemia syndrome. A new hope for patients.

Tryngolza®: A Breakthrough Treatment Approved in the EU for FCS Patients #None #Olezarsen #Tryngolza #FCS

Recommendation for TRYNGOLZA® (olezarsen) Approval for FCS in the EU Sobi and Ionis Pharmaceuticals announce a positive CHMP opinion for TRYNGOLZA in treating familial chylomicronemia syndrome in Europe, highlighting significant clinical trial results.

Recommendation for TRYNGOLZA® (olezarsen) Approval for FCS in the EU #Sweden #Stockholm #Sobi #Olezarsen #Tryngolza

FDA Approves RNA-targeted Therapy for Familial Chylomicronemia Syndrome Olezarsen@is the first approved treatment in the U.S. for FCS, which prevents the body from breaking down fats. The treatment is an@antisense oligonucleotide (ASO).

FDA approved #Tryngolza (also known as #Olezarsen), an investigational, first-in-class, RNA-targeted medicine for the treatment of adults with familial chylomicronemia syndrome (FCS). FCS is a rare genetic disease that prevents the body from breaking down fats. www.asgct.org/publications...

Groundbreaking FDA Approval: TRYNGOLZA™ Becomes First Treatment for Familial Chylomicronemia Syndrome Ionis Pharmaceuticals celebrates the FDA approval of TRYNGOLZA™, the first-ever treatment for adultswith familial chylomicronemia syndrome, transforming patient lives by reducing triglyceride levels significantly.

Groundbreaking FDA Approval: TRYNGOLZA™ Becomes First Treatment for Familial Chylomicronemia Syndrome #United_States #Carlsbad,_California #TRYNGOLZA™ #Olezarsen #Ionis_Pharmaceuticals

Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome | NEJM Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepati...

MedSky🧪 #Cardiosky🫀 Olezarsen, #AcutePancreatitis & Familial Chylomicronemia Syndrome In patients with #familialchylomicronemiasyndrome, #olezarsen may represent a new therapy to reduce plasma triglyceride levels.

www.nejm.org/doi/pdf/10.1...